Pancreatic cancer clinical trial results released

April 3, 2012, The Translational Genomics Research Institute

The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

The findings were announced during the American Association for Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago.

"The most important finding is that this approach is feasible and we are encouraged by preliminary evidence that this approach may benefit some patients," said Dr. Ramesh K. Ramanathan, Medical Director of the Virginia G. Piper Cancer Center at Scottsdale Healthcare, a partnership with .

The completed phase II clinical trial: Therapy Selected by Tumor Molecular Profiling in Patients with Previously Treated Metastatic Pancreatic Cancer, is part of a Stand Up To Cancer (SU2C) Pancreatic Cancer Dream Team consortium created in 2009.

Dr. Ramanathan said this is the first clinical study of pancreatic cancer in which biopsies were done of the tumors and treatments were based on the molecular profiling of pancreatic .

The study showed that biopsies could be safely conducted, and that multiple could be identified by IHC and DNA sequencing (Caris Target Now®), CGH and microarray.

"Survival analysis is premature, but we believe some patients have had benefit," Dr. Ramanathan said.

Forty-nine subjects were accrued between August 2010 and January 2012. Fourteen patients did not start protocol therapy either due to insufficient tumor on or due to worsening cancer related symptoms after biopsy. There were 35 evaluable patients.

In most patients — all of whom had prior chemotherapy — molecular profiling at Caris resulted in two or more IHC targets for therapy and a non-cross resistant regimen could be implemented.

The most common IHC targets were topoisomerase 1 or 2 and Thymidylatesynthase. Only commercially available agents were prescribed. Treatment recommendations were based primarily on IHC markers. Common regimens/ agents recommended were FOLFIRI, FOLFOX, irinotecan and doxorubicin.

Study has completed accrual. One patient treated with FOLFIRI is a one-year survivor.

Genomic (CGH and microarray) assays and pathway analysis are ongoing to understand response and molecular factors identified in the cancer cells..

The study's abstract will be presented at an AACR Late-Breaking Poster Session from 8 a.m.-12 p.m. today at Chicago's McCormick Place convention center.

Explore further: Results of new drug for pancreatic cancer patients published

Related Stories

Results of new drug for pancreatic cancer patients published

October 4, 2011
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new ...

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

July 20, 2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...

'Seena' clinical trials named for pancreatic cancer advocate

December 1, 2011
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic ...

Recommended for you

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.